In SOUND trial (NCT05374603), an open-label, interventional, multi-center, exploratory trial, savolitinib combined with durvalumab will be evaluated in Chinese EGFR wild-type locally advanced or metastatic NSCLC patients with MET alterations. This evidence concerns the gene MET and non-small cell lung carcinoma.